The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000823370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/08/2025
Date registered
Help: Date registered
8/07/2026
Date last updated
Help: Date last updated
8/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
8/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effectiveness of Comprehensive Geriatric Assessment to improve outcomes for Older PeoplE having hip and knee replacement surgery (COPE).
Scientific title
Comprehensive Geriatric Assessment for Older PeoplE having total hip or knee replacement surgery (COPE): A stepped-wedge cluster randomised trial to examine clinical, implementation, and cost effectiveness.
Additional trial identifiers [1] 315241 0
Nil
Universal Trial Number (UTN)
Trial acronym
COPE
Related trial records

Health condition
Health condition(s) studied:
Osteoarthritis 338699 0
Condition category
Condition code
Surgery 334982 334982 0 0
Other surgery
Musculoskeletal 334983 334983 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure

Comprehensive Geriatric Assessment (CGA) is the provision of care by a multidisciplinary team (MDT) pre- and post-operative, to identify medical, social and functional needs of older people and develop and execute an integrated/coordinated care plan that centres around the older person and their values, preferences and goals.

For the purposes of the COPE trial the CGA will be provided to patients undergoing an elective total hip replacement (THR) or knee replacement (TKR).

Comprehensive Geriatric Assessment
Peri-operative CGA-based models of care can be broken down to three key components to improve outcomes:
active pre-operative assessment involves diagnosing and treating medical conditions and addressing modifiable risk and lifestyle modification prior to surgery (such as nutrition, exercise),
a pre-operative management care plan for the MDT, and
post-operative review to actively monitor and prevent complications and provide early detection and management of problems such as dehydration, delirium, infections and cardiac events.

Pre-operative assessment
The pre-operative assessment will include assessment of:
Joint pathology
Frailty
Existing medical conditions, severity, management, ability and plan to optimise.
Medical screening for undiagnosed conditions
Medication reconciliation
Social and functional history
Legal factors including substitute decision-maker, Powers of Attorney, Advance Care Planning documentation.
Examination - physical and cognitive
Routine pathology and ECG, and consideration of testing for cardiac, pulmonary and sleep abnormalities
Identification of patient perceptions, values and preferences
Postoperative risk quantification, monitoring and mitigation plan, and communication with patients and family/carers and the multidisciplinary team


Whilst some hospitals may provide prehabilitation to patients undergoing elective THR or TKR (such as exercise, nutrition, psychology), CGA is a broader, multidomain model that crucially involves a dedicated service that provides person-centred optimisation and shared decision making.

Pre-operative management care plan
Synthesis of assessment findings undertaken by a health care professional, specially trained in the delivery of the CGA intervention (a COPE clinician) and who will coordinate the MDT.

The MDT and the COPE clinician, decide collaboratively with the patient, using a shared decision-making model, whether to a) to pursue surgical intervention or b) to not pursue surgical intervention after considering the risks and benefits.

If the patient decides to pursue surgery, the COPE clinician will coordinate with the surgical team the pathway to surgery maximising optimisation targets to be met (addressing modifiable patient risks in the context of the procedure) and avoiding unnecessary delays. A pre- and post-operative management plan will be developed and discussed with the patient and the multi-disciplinary care team, and the patient will be provided with specific information to prepare them for surgery.

If the patient decides not to pursue surgery, the COPE clinician will provide the patient with alternative or additional management options.

Post-operative review and prevention and treatment of complications
The geriatrician, anaesthetist and surgical team and, when required, intensivist determine the immediate post-operative management based on patient risk assessment, intra-operative and institutional factors and provide an appropriate handover to the relevant MDT members who have input in the post-operative period.

The COPE clinician and MDT collaborate to anticipate, prevent, detect and respond to complications in the patient in the post-operative period.

The post-operative review and management includes (but is not limited to):
Pain management
Management of wound, postoperative orders
Proactive prevention, screening for medical complications and management on occurrence
Early mobility and progression of mobility status
Review of functional status as mobility progresses
Discharge planning

Prior to discharge the COPE clinician will coordinate a post-discharge management plan to ensure the patient’s discharge from the acute care setting is well coordinated.

COPE clinicians will be assigned by the hospital sites. Geriatricians have a high level of expertise in CGA and are key to effectively delivering CGA. Geriatricians will therefore be the first choice to deliver the intervention. However, in case a hospital site does not have geriatricians available to deliver this intervention, the following clinicians can also be employed as COPE clinicians:
A Physician with older adult experience
A Nurse Practitioner with experience treating acute older adults

The MDT will include (but is not limited to) health care professionals from medical, nursing, allied health (including all or a combination of physiotherapy, occupational therapy, dietetics, speech pathology, social work), and pharmacy. The exact make-up of the MDT will be dependent on each individual hospital site and will be developed as part of the implementation planning and contextual adaptation phase of the project.

Pre-operative assessment will be completed between 4 weeks-3 months prior to booked elective surgery.

Post-operative assessment by the COPE clinician will commence within 48 hours of surgery.

The pre-operative assessment will be undertaken as part of an outpatient clinic (to be determined at each site), through a combination of face-to-face and/or telephone-based contact.

The post-operative assessment will be undertaken in the acute hospital setting. Once the patient is discharged from the acute hospital setting, they will be discharged from the intervention.


Intervention code [1] 331851 0
Treatment: Other
Description of the comparator or control
Usual patient care defined as the model of care used for patients undergoing THR and TKR in the hospital prior to being in the study.
Control group
Active

Outcomes
Primary outcome [1] 342611 0
The number of days alive and at home at 30 days post surgery (DAH30).
Timepoint [1] 342611 0
30 days after surgery
Secondary outcome [1] 451539 0
Quality of recovery
Timepoint [1] 451539 0
48 hours post operative and 1 month post operative
Secondary outcome [2] 451540 0
Mobility function
Timepoint [2] 451540 0
Pre operative 48 hours post operative and 1 month post operative
Secondary outcome [3] 451541 0
Decision Regret
Timepoint [3] 451541 0
1 month post operative (surgical patients) or 1 month post meeting with COPE clinician (non surgical patients)
Secondary outcome [4] 451542 0
Post operative complications
Timepoint [4] 451542 0
1 month post operative
Secondary outcome [5] 451543 0
Health related quality of life
Timepoint [5] 451543 0
Pre operative and 1 month post operative
Secondary outcome [6] 452470 0
Cost effectiveness
Timepoint [6] 452470 0
1. At the end of each block within the stepped wedge clinical trial, there will be an audit of training records; and the site leader will complete a diary to report implementation costs and resources 2. At the end of the clinical trial, the hospital administrative admission and cost data for the index admission (admission related to the joint replacement) will be obtained 3. At the end of the clinical trial, the health service administrative admission and cost data for the 30 days following surgery will be obtained
Secondary outcome [7] 452471 0
Implementation effectiveness: Intervention adoption. Are patients being screened appropriately?
Timepoint [7] 452471 0
Periodically checked once a month from date of first participant enrolment until last data collection.
Secondary outcome [8] 458567 0
Implementation effectiveness: Fidelity of implementation.
Timepoint [8] 458567 0
Post patient acute episode of care. This will be assessed using cumulative data at the conclusion of the study.
Secondary outcome [9] 458568 0
Implementation effectiveness: Acceptability and feasibility of the intervention for staff. This will be assessed as a composite outcome.
Timepoint [9] 458568 0
5 weeks post completion of the intervention implementation period
Secondary outcome [10] 458569 0
Implementation effectiveness: Patient satisfaction and acceptability, This will be assessed as a composite outcome.
Timepoint [10] 458569 0
1 month post-operative or post decision for non-surgical patients
Secondary outcome [11] 458571 0
Implementation effectiveness: Barriers and enablers to implementation. This will be assessed as a composite outcome.
Timepoint [11] 458571 0
5 weeks post completion of the intervention implementation period
Secondary outcome [12] 458572 0
Implementation effectiveness: Conditions required for sustainability of the interventions
Timepoint [12] 458572 0
5 weeks post completion of the intervention implementation period
Secondary outcome [13] 462506 0
Post Operative Readmissions
Timepoint [13] 462506 0
1 month post operative
Secondary outcome [14] 462518 0
Intervention sustainability Is it still being implemented?
Timepoint [14] 462518 0
3 months post intervention completion
Secondary outcome [15] 462520 0
Implementation effectiveness: Intervention penetration
Timepoint [15] 462520 0
End of the implementation period

Eligibility
Key inclusion criteria
To be eligible to participate in the study, participants must be undergoing elective THR or TKR at one of the hospital sites, and meet the following inclusion criteria:
- Age greater than or equal to 65 years or greater than or equal to 50 if First Nations, and greater than or equal to 5 on Clinical Frailty Scale; or
- Age greater than or equal to 65 years or greater than or equal to 50 if First Nations and greater than or equal to 3 on American Society of Anaesthesiologists scale of physical health.
Patients undergoing revision (“redo”) surgery are eligible.


Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
A participant will be excluded from the trial if they are unable or refuse to give informed consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
It will not be feasible to blind staff or patients to the intervention.

A blinded statistician using computer generated randomisation methods will randomly allocate hospital sites.

Research staff recruiting participants will remain blinded to the randomisation schedule and will have no contact with the COPE clinician throughout the study to ensure allocation concealment.

Once the patient has been enrolled, the research team staff will notify the project coordinator, if the hospital is in the intervention phase of the trial, the project coordinator will pass the participant’s details on to the COPE clinician performing the intervention.

A trained data collector, blinded to group allocation, will collect primary outcome data.

In order to reduce observer bias, analysis of the primary outcome will be assessed by a statistician who will be blind to group allocation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A blinded statistician using computer generated randomisation methods will randomly allocate hospital sites.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
This is a batched stepped-wedge, cluster-randomised trial that will recruit participants over 18 months, involving 10-12 hospital sites. Hospital sites will be randomised in two batches of five to six hospital sites each.

A batched approach will allow for hospital sites to be recruited in two batches of five or six hospitals each. Cluster randomisation will be used to allow for randomisation to occur at the level of the cluster (hospital) instead of the participant. A stepped-wedge trial has a unidirectional cross-over design where all clusters (hospitals) begin in the control phase and cross over to the intervention at different time points. Each study phase will last 2 months, resulting in a total of 60 trial phases (i.e. 30 intervention phases and 30 control phases).

The design involves an initial control period where no hospital is exposed to the intervention. Then, at each study phase, one new hospital site will be randomised to cross over from control to the intervention and will implement the CGA intervention. By the end of the 18 months study period, all hospitals will have implemented the CGA intervention. The length of time a hospital receives the intervention may vary between 2 months and 10 months (Figure 1 in protocol).

A 2-week transition “lead in” phase is included where the hospital is not considered as being in control or intervention and this period does not contribute to the analysis. This phase will allow time for each site to set up processes and implement the intervention into practice.

Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The sample size was calculated for the primary trial outcome.

With a total of 720 patients (12 patients in each of 6 periods in 10 hospitals), and an intra-hospital correlation of 0.060 (estimated from DAH30 from 336 hip/knee replacements in 12 hospitals in the PADDI trial7), with a cluster autocorrelation of 0.80, 2000 simulated trial datasets with CGA effects estimated using quantile regression with cluster-robust standard errors indicate that a 1.5-day improvement in median DAH30 can be detected with approximately >95% power (alpha=0.05).

Analysis for clinical effectiveness
An intention-to-treat analysis will be conducted. All participants will be included in the analysis. Each hospital will be classified as being in the intervention or the control phase based on their prespecified randomised cross-over time, regardless of whether crossover is achieved at that time.

In the primary analysis, differences in the number of days alive and at home at 30 days post-surgery (DAH30) will be modelled using quantile regression with cluster-robust standard errors to account for clustering of patients within sites, and includes a fixed effect for each step to account for any temporal trend.

Analysis will be controlled for site level factors such as patient case mix characteristics and site level characteristics. This will be done by including both a random effect for hospitals and a random effect for patient case mix. We will also report estimates of intra-cluster correlations.
Secondary analysis will be conducted using similar techniques but using different link functions as appropriate.
Subgroup analyses will be hypothesis generating to assess whether the effect of the intervention varies by:
- level of patient frailty (defined by the Clinical Frailty Scale)
- number and type of comorbidities at hospital admission
- living status
- gender

Secondary analysis will include a per-protocol analysis to a) patients that did not receive the CGA assessment as planned or b) exclude hospital sites that do not sufficiently implement as planned .
All results will be reported with 95% CI, with statistical significance at p< 0.05.

Analysis for implementation process evaluation
Interview and focus group transcripts will be uploaded to NVivo software to facilitate data management and analysis. Data will be analysed using content and thematic analysis using inductive and deductive coding approaches. Deductive coding will be based on appropriate theoretical frameworks and inductive coding will enable the identification of new themes.

Cost data:
The economic evaluation will establish the cost of health service care in the 30 days following surgery (time horizon), and will be inclusive of the index admission, inpatient rehabilitation, outpatient rehabilitation / allied health / medical appointments, via the health service’s administrative admission and cost data. In addition, CGA program costs will be determined via a cost of implementation analysis to determine the per patient cost of CGA (both pre and post-surgery). The per patient cost of CGA, will be added to the index admission cost, for patients under CGA conditions.

Effect data:
Raw scores of the EQ-5D-5L will be converted into a utility index (a score of 0-1 where 0 equals a state of death and 1 equals a state of perfect health), and the change in utility index between pre-surgery and 30 days post-surgery will be used to establish the QALYs gained.

The economic evaluation will use the cost and QALY data, to establish the incremental cost-effectiveness ratio (ICER) for ‘between group’ cost per QALY gained (cost-utility analysis). An a priori a threshold of $50,000 per QALY gained will be used to determine if the CGA model of care is cost effective when compared to usual care, based on previously published thresholds for willingness to pay per QALY gained. The economic evaluation will use Stata software for the analysis, and the ICER analysis will use a bootstrapping technique (1,000 repetitions) with the results presented on a cost-effectiveness plan. Costs will be presented in $AUD 2027, with prior costs inflated by consumer price index to establish a net present value.


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment hospital [1] 29139 0
The Sutherland Hospital - Caringbah
Recruitment hospital [2] 29218 0
Sandringham Hospital - Sandringham
Recruitment hospital [3] 29565 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [4] 29566 0
Barwon Health - Geelong Hospital campus - Geelong
Recruitment hospital [5] 29567 0
Frankston Hospital - Frankston
Recruitment postcode(s) [1] 45445 0
2229 - Caringbah
Recruitment postcode(s) [2] 45526 0
3191 - Sandringham
Recruitment postcode(s) [3] 45890 0
3050 - Parkville
Recruitment postcode(s) [4] 45891 0
3220 - Geelong
Recruitment postcode(s) [5] 45892 0
3199 - Frankston

Funding & Sponsors
Funding source category [1] 319808 0
Government body
Name [1] 319808 0
National health and medical research council
Country [1] 319808 0
Australia
Primary sponsor type
Government body
Name
National Health and Medical Research Council
Address
Country
Australia
Secondary sponsor category [1] 322321 0
University
Name [1] 322321 0
Monash University
Address [1] 322321 0
Country [1] 322321 0
Australia
Secondary sponsor category [2] 322323 0
University
Name [2] 322323 0
University of New South Wales
Address [2] 322323 0
Country [2] 322323 0
Australia
Secondary sponsor category [3] 322324 0
University
Name [3] 322324 0
Deakin University
Address [3] 322324 0
Country [3] 322324 0
Australia
Secondary sponsor category [4] 322325 0
University
Name [4] 322325 0
University of Adelaide
Address [4] 322325 0
Country [4] 322325 0
Australia
Other collaborator category [1] 283636 0
Hospital
Name [1] 283636 0
Alfred Health
Address [1] 283636 0
Country [1] 283636 0
Australia
Other collaborator category [2] 283637 0
Hospital
Name [2] 283637 0
South Western Sydney Local Health District
Address [2] 283637 0
Country [2] 283637 0
Australia
Other collaborator category [3] 283638 0
Hospital
Name [3] 283638 0
South Eastern Sydney Local Health District
Address [3] 283638 0
Country [3] 283638 0
Australia
Other collaborator category [4] 283852 0
Hospital
Name [4] 283852 0
Peninsula Health
Address [4] 283852 0
Country [4] 283852 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318364 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 318364 0
Ethics committee country [1] 318364 0
Australia
Date submitted for ethics approval [1] 318364 0
27/10/2025
Approval date [1] 318364 0
16/12/2025
Ethics approval number [1] 318364 0
122895 (local ref number: 712/25)
Ethics committee name [2] 319707 0
Monash University Human Research Ethics Committee
Ethics committee address [2] 319707 0
Ethics committee country [2] 319707 0
Australia
Date submitted for ethics approval [2] 319707 0
22/01/2026
Approval date [2] 319707 0
23/01/2026
Ethics approval number [2] 319707 0
50798

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143954 0
Prof Janet Anderson
Address 143954 0
Department of Anaesthesiology and Perioperative Medicine Faculty of Medicine, Nursing and Health Sciences Monash University The Alfred Centre 99 Commercial Road Melbourne VIC 3004, Australia
Country 143954 0
Australia
Phone 143954 0
+61 3 99030796
Fax 143954 0
Email 143954 0
Contact person for public queries
Name 143955 0
Abha Somesh
Address 143955 0
Department of Anaesthesiology and Perioperative Medicine Faculty of Medicine, Nursing and Health Sciences Monash University The Alfred Centre 99 Commercial Road Melbourne VIC 3004, Australia
Country 143955 0
Australia
Phone 143955 0
+61 423529902
Fax 143955 0
Email 143955 0
Contact person for scientific queries
Name 143956 0
Janet Anderson
Address 143956 0
Department of Anaesthesiology and Perioperative Medicine Faculty of Medicine, Nursing and Health Sciences Monash University The Alfred Centre 99 Commercial Road Melbourne VIC 3004, Australia
Country 143956 0
Australia
Phone 143956 0
+61 3 99030796
Fax 143956 0
Email 143956 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.